EliMuchtarMD

PubMed

• 137 citations
  Systemic amyloidosis from A (AA) to T (ATTR): a review.
  Eli Muchtar, Angela Dispenzieri, Hila Magen, Martha Grogan, Michelle L. Mauermann
  Journal of Internal Medicine. 2021-03-01
• 42 citations
  Surgical site infections following craniotomy focusing on possible post-operative acquisition of infection: prospective cohort study.
  O. Sneh-Arbib, A. Shiferstein, N. Dagan, Shai Fein, L. Telem
  European Journal of Clinical Microbiology & Infectious Diseases. 2013-06-11
• 475 citations
  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis
  Mical Paul, Vered Shani, Eli Muchtar, Galia Kariv, Eyal Robenshtok
  Antimicrobial Agents and Chemotherapy. 2010-11-01

Journal Articles

• Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation  
  Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Daratumumab-Based Therapy in Patients with Heavily-Pretreated AL Amyloidosis  
  Saurabh Zanwar, Angela Dispenzieri, Wilson Gonsalves, David Dingli, Jithma P Abeykoon, Martha Q Lacy, Shaji Kumar, Nelson Leung, Morie A Gertz, Eli Muchtar, Francis Bu..., Nature
• Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio  
  Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
• Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Centre  
  Sameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology
• Join now to see all

Abstracts/Posters

• BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
  Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long-Term Survivorship with Active Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all